Published in PLoS Comput Biol on April 28, 2011
Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol (2012) 2.63
A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci Signal (2014) 1.63
Large-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-Class Collaborative Filtering and Its Application to Drug Repurposing. PLoS Comput Biol (2016) 1.42
Automatic construction of a large-scale and accurate drug-side-effect association knowledge base from biomedical literature. J Biomed Inform (2014) 1.18
ProBiS-2012: web server and web services for detection of structurally similar binding sites in proteins. Nucleic Acids Res (2012) 1.11
Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention. Curr Opin Oncol (2013) 1.03
Harnessing Big Data for Systems Pharmacology. Annu Rev Pharmacol Toxicol (2016) 0.99
Drug-target interaction prediction through domain-tuned network-based inference. Bioinformatics (2013) 0.99
Networking for new drugs. Nat Med (2011) 0.97
Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key. PLoS One (2013) 0.94
ProBiS-database: precalculated binding site similarities and local pairwise alignments of PDB structures. J Chem Inf Model (2012) 0.93
A Data Analysis Pipeline Accounting for Artifacts in Tox21 Quantitative High-Throughput Screening Assays. J Biomol Screen (2015) 0.93
Controllability in cancer metabolic networks according to drug targets as driver nodes. PLoS One (2013) 0.91
An inhibitor of HIV-1 protease modulates constitutive eIF2α dephosphorylation to trigger a specific integrated stress response. Proc Natl Acad Sci U S A (2015) 0.90
Computing Clinically Relevant Binding Free Energies of HIV-1 Protease Inhibitors. J Chem Theory Comput (2014) 0.89
Towards structural systems pharmacology to study complex diseases and personalized medicine. PLoS Comput Biol (2014) 0.87
Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity. Mol Pharmacol (2013) 0.87
Pocket-based drug design: exploring pocket space. AAPS J (2012) 0.86
Pharmacological eEF2K activation promotes cell death and inhibits cancer progression. EMBO Rep (2016) 0.86
Achievements and challenges in structural bioinformatics and computational biophysics. Bioinformatics (2014) 0.84
Combining automatic table classification and relationship extraction in extracting anticancer drug-side effect pairs from full-text articles. J Biomed Inform (2014) 0.84
Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem. Front Pharmacol (2015) 0.83
Associations between HIV and human pathways revealed by protein-protein interactions and correlated gene expression profiles. PLoS One (2012) 0.83
Comparing a knowledge-driven approach to a supervised machine learning approach in large-scale extraction of drug-side effect relationships from free-text biomedical literature. BMC Bioinformatics (2015) 0.82
Computational analysis and predictive modeling of polymorph descriptors. Chem Cent J (2013) 0.81
Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach. J Med Chem (2016) 0.81
Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity. F1000Res (2015) 0.80
DASPfind: new efficient method to predict drug-target interactions. J Cheminform (2016) 0.79
Nelfinavir impairs glycosylation of herpes simplex virus 1 envelope proteins and blocks virus maturation. Adv Virol (2015) 0.79
Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology. Sci Rep (2016) 0.79
What does it take to synergistically combine sub-potent natural products into drug-level potent combinations? PLoS One (2012) 0.79
Identification of distant drug off-targets by direct superposition of binding pocket surfaces. PLoS One (2013) 0.78
A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer. Oncotarget (2015) 0.78
Drug repurposing to target Ebola virus replication and virulence using structural systems pharmacology. BMC Bioinformatics (2016) 0.78
Providing data science support for systems pharmacology and its implications to drug discovery. Expert Opin Drug Discov (2016) 0.78
Nelfinavir is effective against human cervical cancer cells in vivo: a potential treatment modality in resource-limited settings. Drug Des Devel Ther (2016) 0.77
New insights into the in silico prediction of HIV protease resistance to nelfinavir. PLoS One (2014) 0.77
Nelfinavir and nelfinavir analogs block site-2 protease cleavage to inhibit castration-resistant prostate cancer. Sci Rep (2015) 0.76
Drug repurposing a reality: from computers to the clinic. Expert Rev Clin Pharmacol (2013) 0.76
Targeting the off-targets: a computational bioinformatics approach to understanding the polypharmacology of nelfinavir. Expert Rev Clin Pharmacol (2011) 0.75
Improved genome-scale multi-target virtual screening via a novel collaborative filtering approach to cold-start problem. Sci Rep (2016) 0.75
Drug-target interaction prediction via class imbalance-aware ensemble learning. BMC Bioinformatics (2016) 0.75
SInCRe-structural interactome computational resource for Mycobacterium tuberculosis. Database (Oxford) (2015) 0.75
Modeling enzyme-ligand binding in drug discovery. J Cheminform (2015) 0.75
Molecular mechanisms involved in the side effects of fatty acid amide hydrolase inhibitors: a structural phenomics approach to proteome-wide cellular off-target deconvolution and disease association. NPJ Syst Biol Appl (2016) 0.75
Computational discovery and experimental verification of tyrosine kinase inhibitor pazopanib for the reversal of memory and cognitive deficits in rat model neurodegeneration. Chem Sci (2015) 0.75
Scalable molecular dynamics with NAMD. J Comput Chem (2005) 59.49
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
The protein kinase complement of the human genome. Science (2002) 35.36
The Amber biomolecular simulation programs. J Comput Chem (2005) 28.84
AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem (2010) 25.20
Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science (2008) 20.68
A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol (2005) 12.22
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 10.98
Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res (2000) 10.78
Predicting new molecular targets for known drugs. Nature (2009) 9.71
Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins (2004) 9.15
Diversity and complexity in DNA recognition by transcription factors. Science (2009) 9.07
Force fields for protein simulations. Adv Protein Chem (2003) 8.70
Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol (2008) 8.51
Relating protein pharmacology by ligand chemistry. Nat Biotechnol (2007) 6.61
Generalized born models of macromolecular solvation effects. Annu Rev Phys Chem (2000) 6.55
Calculation of protein-ligand binding affinities. Annu Rev Biophys Biomol Struct (2007) 6.12
Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov (2010) 5.76
Harmonic dynamics of proteins: normal modes and fluctuations in bovine pancreatic trypsin inhibitor. Proc Natl Acad Sci U S A (1983) 5.27
Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov (2006) 4.56
Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today (2006) 4.24
Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med (2010) 3.98
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 3.84
Performance comparison of generalized born and Poisson methods in the calculation of electrostatic solvation energies for protein structures. J Comput Chem (2004) 3.83
Targeting the cancer kinome through polypharmacology. Nat Rev Cancer (2010) 3.74
Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol (2006) 3.63
Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets. PLoS Comput Biol (2010) 3.23
A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov (2007) 3.22
Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov (2009) 3.20
The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci (2005) 3.02
Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol (2009) 2.84
Fragment-based lead discovery. Nat Rev Drug Discov (2004) 2.83
Binding of small-molecule ligands to proteins: "what you see" is not always "what you get". Structure (2009) 2.83
Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des (2007) 2.79
Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci U S A (2007) 2.67
Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments. Proc Natl Acad Sci U S A (2008) 2.44
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol (2007) 2.43
Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol (2009) 2.35
Models from experiments: combinatorial drug perturbations of cancer cells. Mol Syst Biol (2008) 2.33
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Predicting absolute ligand binding free energies to a simple model site. J Mol Biol (2007) 2.19
Can we rationally design promiscuous drugs? Curr Opin Struct Biol (2006) 2.06
Drug-target residence time: critical information for lead optimization. Curr Opin Chem Biol (2010) 1.97
Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput Biol (2010) 1.97
Network pharmacology. Nat Biotechnol (2007) 1.95
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem (2008) 1.88
Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal (2006) 1.87
HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res (2005) 1.81
Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. J Comput Chem (2010) 1.77
RTK/Ras/MAPK signaling. WormBook (2006) 1.75
Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov (2007) 1.73
Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol (2008) 1.70
A robust and efficient algorithm for the shape description of protein structures and its application in predicting ligand binding sites. BMC Bioinformatics (2007) 1.70
Cracking the phosphatase code: docking interactions determine substrate specificity. Sci Signal (2009) 1.67
Calculation of absolute protein-ligand binding affinity using path and endpoint approaches. Biophys J (2005) 1.65
Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther (2008) 1.65
Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res (2010) 1.59
Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol (2009) 1.49
A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery. Bioinformatics (2009) 1.46
Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J Cell Sci (2008) 1.46
Use of MM-PB/SA in estimating the free energies of proteins: application to native, intermediates, and unfolded villin headpiece. Proteins (2000) 1.46
eHiTS: a new fast, exhaustive flexible ligand docking system. J Mol Graph Model (2006) 1.44
A mathematical model of combination therapy using the EGFR signaling network. Biosystems (2005) 1.23
Computational methodologies for modelling, analysis and simulation of signalling networks. Brief Bioinform (2006) 1.22
A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology. PLoS Comput Biol (2010) 1.19
Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. Phys Rev E Stat Nonlin Soft Matter Phys (2005) 1.19
Selectivity and promiscuity in the interaction network mediated by protein recognition modules. FEBS Lett (2004) 1.12
In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening. Pharm Res (2010) 1.05
Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry (2009) 1.01
Importance of ligand reorganization free energy in protein-ligand binding-affinity prediction. J Am Chem Soc (2009) 0.96
Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells. Breast Cancer Res (2010) 0.96
Conciliating binding efficiency and polypharmacology. Trends Pharmacol Sci (2009) 0.91
Molecular dynamics simulations of 2-amino-6-arylsulphonylbenzonitriles analogues as HIV inhibitors: interaction modes and binding free energies. Chem Biol Drug Des (2010) 0.89
Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1. Anticancer Drugs (2006) 0.87
Investigation of the interaction between the large and small subunits of potato ADP-glucose pyrophosphorylase. PLoS Comput Biol (2009) 0.87
Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. J Med Chem (2008) 0.87
Multi-kinase inhibitors create buzz at ASCO. Nat Biotechnol (2005) 0.86
Ras promotes cell survival by antagonizing both JNK and Hid signals in the Drosophila eye. BMC Dev Biol (2009) 0.86
Molecular modeling of human cytochrome P450 2W1 and its interactions with substrates. J Mol Graph Model (2009) 0.83
Studies of chirality effect of 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine on p38alpha by molecular dynamics simulations and free energy calculations. J Comput Aided Mol Des (2009) 0.78
The Protein Data Bank. Acta Crystallogr D Biol Crystallogr (2002) 14.44
The Protein Data Bank: unifying the archive. Nucleic Acids Res (2002) 12.37
The RCSB Protein Data Bank: a redesigned query system and relational database based on the mmCIF schema. Nucleic Acids Res (2005) 7.81
The RCSB Protein Data Bank: redesigned web site and web services. Nucleic Acids Res (2010) 7.68
Ten simple rules for getting published. PLoS Comput Biol (2005) 7.22
The RCSB PDB information portal for structural genomics. Nucleic Acids Res (2006) 6.36
The RCSB Protein Data Bank: new resources for research and education. Nucleic Acids Res (2012) 5.73
BioLit: integrating biological literature with databases. Nucleic Acids Res (2008) 4.85
SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res (2007) 3.82
Ten simple rules for getting grants. PLoS Comput Biol (2006) 3.13
Ten simple rules for a successful collaboration. PLoS Comput Biol (2007) 3.12
Using multiple structure alignments, fast model building, and energetic analysis in fold recognition and homology modeling. Proteins (2003) 3.04
BioJava: an open-source framework for bioinformatics in 2012. Bioinformatics (2012) 2.94
Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol (2009) 2.84
The Molecular Biology Toolkit (MBT): a modular platform for developing molecular visualization applications. BMC Bioinformatics (2005) 2.60
Ten simple rules for making good oral presentations. PLoS Comput Biol (2007) 2.57
Structural evolution of the protein kinase-like superfamily. PLoS Comput Biol (2005) 2.48
Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments. Proc Natl Acad Sci U S A (2008) 2.44
Phylogeny determined by protein domain content. Proc Natl Acad Sci U S A (2005) 2.37
Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol (2009) 2.35
Outcome of a workshop on archiving structural models of biological macromolecules. Structure (2006) 2.32
Pre-calculated protein structure alignments at the RCSB PDB website. Bioinformatics (2010) 2.28
ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics (2008) 2.26
Open access: taking full advantage of the content. PLoS Comput Biol (2008) 2.14
Antibody-protein interactions: benchmark datasets and prediction tools evaluation. BMC Struct Biol (2007) 2.14
Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res (2008) 2.14
Modern proteomes contain putative imprints of ancient shifts in trace metal geochemistry. Proc Natl Acad Sci U S A (2006) 2.10
Immune epitope database analysis resource. Nucleic Acids Res (2012) 2.09
The Mycobacterium tuberculosis drugome and its polypharmacological implications. PLoS Comput Biol (2010) 2.07
Functional coverage of the human genome by existing structures, structural genomics targets, and homology models. PLoS Comput Biol (2005) 2.04
An ontology driven architecture for derived representations of macromolecular structure. Bioinformatics (2002) 1.97
Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput Biol (2010) 1.97
Biodiversity data should be published, cited, and peer reviewed. Trends Ecol Evol (2013) 1.97
Ten simple rules for reviewers. PLoS Comput Biol (2006) 1.84
Ten simple rules for selecting a postdoctoral position. PLoS Comput Biol (2006) 1.77
Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol (2011) 1.76
History of biological metal utilization inferred through phylogenomic analysis of protein structures. Proc Natl Acad Sci U S A (2010) 1.71
A robust and efficient algorithm for the shape description of protein structures and its application in predicting ligand binding sites. BMC Bioinformatics (2007) 1.70
PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res (2010) 1.69
Computational biology resources lack persistence and usability. PLoS Comput Biol (2008) 1.65
CE-MC: a multiple protein structure alignment server. Nucleic Acids Res (2004) 1.64
Topic pages: PLoS Computational Biology meets Wikipedia. PLoS Comput Biol (2012) 1.60
Quantifying reproducibility in computational biology: the case of the tuberculosis drugome. PLoS One (2013) 1.56
Ten simple rules for a good poster presentation. PLoS Comput Biol (2007) 1.55
Partitioning protein structures into domains: why is it so difficult? J Mol Biol (2006) 1.51
Biocurators: contributors to the world of science. PLoS Comput Biol (2006) 1.46
A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery. Bioinformatics (2009) 1.46
Toward consistent assignment of structural domains in proteins. J Mol Biol (2004) 1.42
Intrinsic evaluation of text mining tools may not predict performance on realistic tasks. Pac Symp Biocomput (2008) 1.40
In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators. PLoS Comput Biol (2007) 1.40
Ten simple rules for starting a company. PLoS Comput Biol (2012) 1.39
Curation of complex, context-dependent immunological data. BMC Bioinformatics (2006) 1.36
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther (2005) 1.36
On the role of structural information in remote homology detection and sequence alignment: new methods using hybrid sequence profiles. J Mol Biol (2003) 1.34
Teaching bioinformatics at the secondary school level. PLoS Comput Biol (2011) 1.34
Ten simple rules for doing your best research, according to Hamming. PLoS Comput Biol (2007) 1.32
Superimpose: a 3D structural superposition server. Nucleic Acids Res (2008) 1.31
SuperTarget goes quantitative: update on drug-target interactions. Nucleic Acids Res (2011) 1.29
Ten simple rules for organizing a scientific meeting. PLoS Comput Biol (2008) 1.26
Structure-based systems biology for analyzing off-target binding. Curr Opin Struct Biol (2011) 1.25
Integration of open access literature into the RCSB Protein Data Bank using BioLit. BMC Bioinformatics (2010) 1.22
A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology. PLoS Comput Biol (2010) 1.19
A biologist's guide to synchrotron facilities: the BioSync web resource. Trends Biochem Sci (2002) 1.15
An ontology for immune epitopes: application to the design of a broad scope database of immune reactivities. Immunome Res (2005) 1.15
Exploiting sequence and structure homologs to identify protein-protein binding sites. Proteins (2006) 1.14
Regulation of Nur77 expression by β-catenin and its mitogenic effect in colon cancer cells. FASEB J (2010) 1.14
EpitopeViewer: a Java application for the visualization and analysis of immune epitopes in the Immune Epitope Database and Analysis Resource (IEDB). Immunome Res (2007) 1.10
The evolutionary history of protein domains viewed by species phylogeny. PLoS One (2009) 1.09
Epidemiological and etiological characteristics of hand, foot, and mouth disease in Ningbo, China, 2008-2011. J Clin Virol (2012) 1.09
Nothing about protein structure classification makes sense except in the light of evolution. Curr Opin Struct Biol (2009) 1.07
Application of protein structure alignments to iterated hidden Markov model protocols for structure prediction. BMC Bioinformatics (2006) 1.05
Ten simple rules for graduate students. PLoS Comput Biol (2007) 1.04
Wiggle-predicting functionally flexible regions from primary sequence. PLoS Comput Biol (2006) 1.03
A machine learning-based method to improve docking scoring functions and its application to drug repurposing. J Chem Inf Model (2011) 1.03
Structural analysis of polarizing indels: an emerging consensus on the root of the tree of life. Biol Direct (2009) 1.01
SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison. Nucleic Acids Res (2010) 1.00
Statistically rigorous automated protein annotation. Bioinformatics (2004) 0.97
Proviral insertion in murine lymphomas 2 (PIM2) oncogene phosphorylates pyruvate kinase M2 (PKM2) and promotes glycolysis in cancer cells. J Biol Chem (2013) 0.95
Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma. Cancer Res (2010) 0.95
Institutional Profile: University of California San Diego Pharmacogenomics Education Program (PharmGenEd™): bridging the gap between science and practice. Pharmacogenomics (2011) 0.94
TRANSLATING BIOLOGY: TEXT MINING TOOLS THAT WORK. Pac Symp Biocomput (2008) 0.94
Metagenomic insights into metabolic capacities of the gut microbiota in a fungus-cultivating termite (Odontotermes yunnanensis). PLoS One (2013) 0.94
What Big Data means to me. J Am Med Inform Assoc (2014) 0.94
Assigning new GO annotations to protein data bank sequences by combining structure and sequence homology. Proteins (2005) 0.93
IEDB-3D: structural data within the immune epitope database. Nucleic Acids Res (2010) 0.93
PLoS Computational Biology conference postcards from PSB 2010. PLoS Comput Biol (2010) 0.92
A comparative proteomics resource: proteins of Arabidopsis thaliana. Genome Biol (2003) 0.92
Limitations of Ab initio predictions of peptide binding to MHC class II molecules. PLoS One (2010) 0.92
dConsensus: a tool for displaying domain assignments by multiple structure-based algorithms and for construction of a consensus assignment. BMC Bioinformatics (2010) 0.91
Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence. Int J Antimicrob Agents (2012) 0.90